La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Yantai Dongcheng Pharmaceutical GroupLtd Crescita futura

Future criteri di controllo 3/6

Yantai Dongcheng Pharmaceutical GroupLtd prevede che gli utili e i ricavi cresceranno rispettivamente di 23% e 11.8% all'anno. Si prevede che l'EPS crescerà di 23% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 7.4% in 3 anni.

Informazioni chiave

23.0%

Tasso di crescita degli utili

23.0%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	34.6%
Tasso di crescita dei ricavi	11.8%
Rendimento futuro del capitale proprio	7.4%
Copertura analitica	Low
Ultimo aggiornamento	24 Jul 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) Business Is Yet to Catch Up With Its Share Price

Jul 12

News Flash: 7 Analysts Think Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SZSE:002675) Earnings Are Under Threat

May 06

Yantai Dongcheng Pharmaceutical GroupLtd's (SZSE:002675) Problems Go Beyond Weak Profit

May 05

Is Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) A Risky Investment?

Mar 15

Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) P/E Is On The Mark

Feb 27

Previsioni di crescita degli utili e dei ricavi

SZSE:002675 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	4,279	438	N/A	824	3
12/31/2025	3,717	367	N/A	752	4
12/31/2024	3,357	300	N/A	728	4
3/31/2024	3,072	224	-340	204	N/A
12/31/2023	3,276	210	-235	277	N/A
9/30/2023	3,427	263	35	490	N/A
6/30/2023	3,603	323	199	664	N/A
3/31/2023	3,554	302	467	853	N/A
1/1/2023	3,583	307	607	997	N/A
9/30/2022	3,858	220	415	986	N/A
6/30/2022	3,851	165	292	833	N/A
3/31/2022	3,902	140	295	846	N/A
1/1/2022	3,912	152	413	944	N/A
9/30/2021	3,637	341	445	788	N/A
6/30/2021	3,599	353	702	1,023	N/A
3/31/2021	3,596	411	333	618	N/A
12/31/2020	3,419	418	310	573	N/A
9/30/2020	3,395	214	339	645	N/A
6/30/2020	3,312	196	149	443	N/A
3/31/2020	3,172	164	508	760	N/A
12/31/2019	2,993	155	446	696	N/A
9/30/2019	2,877	366	335	500	N/A
6/30/2019	2,709	347	458	577	N/A
3/31/2019	2,467	302	305	457	N/A
12/31/2018	2,333	280	372	493	N/A
9/30/2018	2,098	228	458	600	N/A
6/30/2018	1,842	212	301	444	N/A
3/31/2018	1,679	185	235	339	N/A
12/31/2017	1,596	173	N/A	209	N/A
9/30/2017	1,511	172	N/A	79	N/A
6/30/2017	1,377	149	N/A	106	N/A
3/31/2017	1,245	145	N/A	106	N/A
12/31/2016	1,158	131	N/A	196	N/A
9/30/2016	1,014	119	N/A	210	N/A
6/30/2016	903	95	N/A	109	N/A
3/31/2016	852	83	N/A	103	N/A
12/31/2015	795	90	N/A	67	N/A
9/30/2015	725	94	N/A	36	N/A
6/30/2015	724	99	N/A	40	N/A
3/31/2015	727	103	N/A	-16	N/A
12/31/2014	751	104	N/A	52	N/A
9/30/2014	786	99	N/A	2	N/A
6/30/2014	783	96	N/A	-10	N/A
3/31/2014	782	91	N/A	66	N/A
12/31/2013	775	101	N/A	-21	N/A
9/30/2013	718	97	N/A	28	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 002675 ( 23% all'anno) è superiore al tasso di risparmio ( 2.9% ).

Guadagni vs Mercato: Si prevede che gli utili di 002675 ( 23% all'anno) cresceranno più rapidamente del mercato CN ( 21.8% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 002675 cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di 002675 ( 11.8% all'anno) crescerà più lentamente rispetto al mercato CN ( 13.4% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 002675 ( 11.8% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 002675 sarà basso tra 3 anni ( 7.4 %).

Yantai Dongcheng Pharmaceutical GroupLtd Crescita futura

Future criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased by 12% to CN¥17.80

Consensus EPS estimates fall by 36%

Recent updates

Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) Business Is Yet to Catch Up With Its Share Price

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Price target decreased by 12% to CN¥17.80

News Flash: 7 Analysts Think Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SZSE:002675) Earnings Are Under Threat

Yantai Dongcheng Pharmaceutical GroupLtd's (SZSE:002675) Problems Go Beyond Weak Profit

Consensus EPS estimates fall by 36%

Yantai Dongcheng Pharmaceutical Group Co.,Ltd., Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Yantai Dongcheng Pharmaceutical Group Co.,Ltd., Annual General Meeting, May 17, 2024

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Is Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) A Risky Investment?

Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) P/E Is On The Mark

Investor sentiment deteriorates as stock falls 15%

Investor sentiment deteriorates as stock falls 15%

Now 25% undervalued after recent price drop

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Now 21% undervalued

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.20 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.14 in 2Q 2022)

High number of new and inexperienced directors

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 10 July 2023

Now 21% undervalued after recent price drop

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Approves Cash Dividend for 2022

Yantai Dongcheng Pharmaceutical Group Co.,Ltd., Annual General Meeting, May 19, 2023

First quarter 2023 earnings released: EPS: CN¥0.061 (vs CN¥0.069 in 1Q 2022)

Now 21% undervalued

Third quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.13 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.11 in 2Q 2021)

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Announces Final Cash Dividend on A Shares for 2021, Payable on 09 June 2022

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Approves Cash Dividend for the Year 2021

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Proposes Final Cash Dividend for the Year 2021

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.15 in 3Q 2020)

Yantai Dingying Investment Partnership (Limited) Partnership) and Chen Xiaoyuan acquired 25% stake in Shanghai Lannacheng Biotechnology Co., Ltd. from Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SZSE:002675) and Xu Ye.

Second quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.18 in 2Q 2020)

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Approves Cash Dividend for the Year 2020, Payable on 4 June 2021

Full year 2020 earnings released: EPS CN¥0.52 (vs CN¥0.19 in FY 2019)

New 90-day low: CN¥18.22

New 90-day low: CN¥18.29

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Announces Executive Changes

New 90-day low: CN¥19.30

Investor sentiment deteriorated over the past week

New 90-day low: CN¥21.28

New 90-day high: CN¥25.90

Third quarter earnings released

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. to Report Q3, 2020 Results on Oct 27, 2020

First half earnings released

New 90-day high - CN¥24.97

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. to Report First Half, 2020 Results on Aug 07, 2020

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita